TelyRx Holdings Inc. has reported disappointing earnings, missing estimates significantly as it navigates a challenging market landscape.
TelyRx Holdings Inc. (TELY.TO) has released its latest earnings report for the fiscal period ending June 30, 2026, revealing a stark earnings miss. The company reported an EPS of -$0.12, falling short of the estimated -$0.06, marking a 100% surprise to the downside. This continues a trend of underperformance, raising questions about the company's future prospects.
Recent earnings trend
Advertisement
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeAdvertisement
Market cap
$71.76M
52W high
$4.25
52W low
$2.00
1W change
-12.73%
Analyst Price Targets
Based on analyst covering TELY
Wall Street analysts forecast TELY stock price to rise 150.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+150.0% Upside
Current Price
C$2.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
108.9%
Annualized
90-Day Vol
102.0%
Annualized
Trend (90d)
-41.6%
Annualized drift
90d Mean
C$2.07
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.28 | C$1.57 – C$3.33 |
| 60 trading days | C$2.17 | C$1.28 – C$3.70 |
| 90 trading days | C$2.07 | C$1.08 – C$3.96 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-10 | -0.1200 | -0.0600 | -100.0% |
| 2026-03-31 | 2026-05-12 | -0.2900 | -0.0300 | -866.7% |
Advertisement
Investor takeaway: Investors should take note of TelyRx's ongoing struggle to meet earnings expectations, as this marks the second consecutive quarter of negative surprises. The stock's recent performance and lack of positive momentum may warrant caution.
Bull case
TelyRx has shown strong revenue growth, with total revenue reaching $22.4 million for the quarter. This indicates a growing demand for its digital pharmacy services. The company has also recently surpassed one million prescriptions filled, reflecting a solid market position.
Bear case
The significant earnings miss and the trend of negative surprises over the last two quarters raise concerns about TelyRx's operational challenges and profitability. With a profit margin of -18.17% and an EPS (TTM) of -0.57, the company is struggling to convert revenue into profit, which could deter potential investors.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
